NY man gives a peek into Pfizer's COVID-19 vaccine trial
Phase three of Pfizer's trials was done with 44,000 people, but this last stretch of the trial is the largest and most diverse pool the company has used. It included different ethnicities, teens as young as 16 and people with compromised immune systems.
•
Nov 10, 2020, 3:13 AM
•
Updated 1,354 days ago
Share:
More Stories
Hometown Heroes in New York City
2ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
310ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
317ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
331ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
331ds agoHometown Heroes in New York City
2ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
310ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
317ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
331ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
331ds agoWhat is it like being part of a clinical trial for the COVID-19 vaccine? One New York man gave News 12 some insight on his experience.
Phase three of Pfizer's trials was done with 44,000 people, but this last stretch of the trial is the largest and most diverse pool the company has used. It included different ethnicities, teens as young as 16 and people with compromised immune systems.
Even back in August, Pfizer described the vaccine as "well tolerated" because fewer than 20% of participants had mild to moderate symptoms.
News 12 spoke to a White Plains man who is a phase three participant. Because it's a double-blind study, we don't know if he received the vaccine, but he said he had no symptoms or issues from the trial.
"You know, I'm not a health care worker. So I can't contribute in that way. I'm not an essential worker, so I can't help in that way, either. So there's different things than everyone can do," says Barry Corvin.
The retiree says he got his first shot back in July. He says he wasn't too worried, and his wife was supportive.
"The risks certainly were worth the reward of either finding out if this works. Or, if it doesn't work, that's just ... you're figuring out something that doesn't work, right?" says Colvin.
A study in the medical journal Pediatrics says 1 in 5 parents are vaccine hesitant. Colvin says to those who are worried -- to each their own -- but he hopes those people will utilize precautions such as wearing masks.
Pfizer is hoping to submit the vaccine for regulatory approval next week with a goal to start distribution by the end of the year.
